Advances in the treatment of BRAF-mutant low-grade glioma with MAPK inhibitors
- PMID: 38590382
- PMCID: PMC10998999
- DOI: 10.21037/tp-23-541
Advances in the treatment of BRAF-mutant low-grade glioma with MAPK inhibitors
Keywords: BRAF mutation; Pediatric; low-grade glioma; molecular targeted therapies; pediatric clinical trials.
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-541/coif). The author reports funding from the National Institutes of Health (Nos. NO1-CM-42216 and R01CA258381). The author has no other conflicts of interest to declare.
Comment on
-
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.J Clin Oncol. 2023 Jan 20;41(3):664-674. doi: 10.1200/JCO.22.01000. Epub 2022 Nov 14. J Clin Oncol. 2023. PMID: 36375115 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials